CN102775427B - Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs - Google Patents

Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs Download PDF

Info

Publication number
CN102775427B
CN102775427B CN201210230665.2A CN201210230665A CN102775427B CN 102775427 B CN102775427 B CN 102775427B CN 201210230665 A CN201210230665 A CN 201210230665A CN 102775427 B CN102775427 B CN 102775427B
Authority
CN
China
Prior art keywords
tetrathiazomycin
compound
preparation
scsio00652
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210230665.2A
Other languages
Chinese (zh)
Other versions
CN102775427A (en
Inventor
鞠建华
周潇
黄洪波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China Sea Institute of Oceanology of CAS
Original Assignee
South China Sea Institute of Oceanology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China Sea Institute of Oceanology of CAS filed Critical South China Sea Institute of Oceanology of CAS
Priority to CN201210230665.2A priority Critical patent/CN102775427B/en
Publication of CN102775427A publication Critical patent/CN102775427A/en
Priority to PCT/CN2012/087016 priority patent/WO2014005408A1/en
Application granted granted Critical
Publication of CN102775427B publication Critical patent/CN102775427B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/185—Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/04—Actinomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides antibiotic Tetrathiazomycin A and preparation method thereof and application in preparation of anti-tumor drugs. Its structural formula of TetrathiazomycinA is as shown in the formula (I). The present invention isolated new compound Tetrathiazomycin A with anti-tumor activity from the fermentation culture medium of actinomyces Marinactinospora thermotoleransSCSIO00652, new approach is opened for the preparation of compound Tetrathiazomycin A, and the compound of the present invention Tetrathiazomycin A has preferable anti-tumor activity, lead compound can be provided for the exploitation of anti-tumor drug using preparing in anti-tumor drug.
Figure DDA00001851316500011

Description

Microbiotic Tetrathiazomycin A and preparation method thereof and the application in preparing antitumor drug
Technical field:
The invention belongs to industrial microorganism field, be specifically related to new microbiotic TetrathiazomycinA and preparation method thereof and the application in preparing antitumor drug.
Background technology:
Malignant tumour is one of principal disease of current serious harm human life and quality of life, has now become China resident's underlying cause of death, accounts for the cause of death more than 20%.Since the second half in 20th century, world's malignant tumour and death are all in rising trend, and especially after the seventies, malignant tumour is with average annual 3% ~ 5% speed increase.World Health Organization's prediction, to the year two thousand twenty, will have 2,000 ten thousand de novo malignancy cases, and wherein death toll reaches 1,200 ten thousand, and the overwhelming majority will occur in developing country.In three large therapies of malignant tumour, pharmacological agent takies consequence.In synthetic chemistry class medicine, majority all be take natural antitumor activeconstituents as lead compound.It is reported, within 1984, to nineteen ninety-five, natural product accounts for listing the more than 60% of antitumor drug, 1995-1999,3 natural product derivatives are as new antitumor drug listing, and as can be seen here, natural product is the important sources of the unique antitumor drug of novel structure and effect.The polypeptide compounds of finding at present has biologic activity widely, it is reported, the cyclic peptide that contains thiazole ring and oxazole ring has very strong cytotoxic activity, for example the IC of Urukthapelstatin A to Human Lung Cancer cell 50value is surprising has reached 12nM.
Summary of the invention:
First object of the present invention is to provide new lactam compound Tetrathiazomycin A or its salt containing four thiazoles with anti-tumor activity.
Lactam compound Tetrathiazomycin A or its salt that contains four thiazoles of the present invention, its structure is as shown in formula I:
Second object of the present invention is to provide the preparation method of compound Tetrathiazomycin A, it is characterized in that, described compound Tetrathiazomycin A is that preparation separation obtains from the fermenting culture of actinomycetes Marinactinospora thermotolerans SCSIO00652.
Preferably from the fermenting culture of actinomycetes Marinactinospora thermotolerans SCSIO00652, preparing separation by the following method obtains Tetrathiazomycin A, and concrete steps are as follows:
A) prepare the fermenting culture of actinomycetes Marinactinospora thermotolerans SCSIO00652, the fermented liquid of this fermenting culture and mycelium are separated, fermented liquid is extracted with ethyl acetate, and ethyl acetate obtains extractum A mutually after concentrated;
B) extractum A is through purification on normal-phase silica gel column chromatography, using chloroform/methanol as eluent, from volume ratio 100:0 ~ 1:1, carry out gradient elution, collect the cut Fr.5-8 that chloroform/methanol volume ratio 92:8 ~ 1:1 gradient elution gets off, again through silica gel column chromatography, by ethyl acetate/methanol as eluent, from volume ratio 94:6 ~ 8:2, carry out gradient elution, collected volume is than the component Fr.5-8-1 of 9:1 ~ 8:2 wash-out, again through the anti-phase medium pressure liquid chromatography of ODS, methanol/water gradient elution with volume fraction from 10% ~ 100%, the cut that the methanol/water gradient elution of collected volume mark 80 ~ 90% gets off, finally by obtaining Tetrathiazomycin A after high-efficient liquid phase chromatogram purification.
The fermenting culture of the preparation Marinactinospora thermotolerans SCSIO00652 of described a) step is prepared by the following method: by the Marinactinospora thermotolerans SCSIO00652 access seed culture medium of activation, 28 ° of C, 200rpm, cultivate 4d and make seed liquor, seed liquor is received in fermention medium by 10% inoculum size, 28 ° of C, 200rpm, shaking culture 7d, and make fermenting culture, described seed culture medium and the formula of fermention medium are all to contain in every liter of substratum: starch 10g, (NH 4) 2sO 42g, K 2hPO 41g, MgSO 47H 2o1g, NaCl1g, peptone 1g, yeast extract powder 05g, trace element solution0.1mL, thick sea salt 30g, surplus is water, pH7.4.
The 3rd object of the present invention is to provide the application of Marinactinospora thermotolerans SCSIO00652 in preparing compound Tetrathiazomycin A.
The present invention found through experiments, Tetrathiazomycin A of the present invention is to neuroglial cytoma strain (SF-268), breast carcinoma cell strain (MCF-7), National People's Congress's sclc cell line (NCI-H460) and human liver cancer cell (HepG-2) have good cytotoxic activity, its IC 50be respectively 38 * 10 -2μ M, 43 * 10 -2μ M, 47 * 10 -2μ M and 52 * 10 -2μ M, can be applicable to prepare antitumor drug.
Therefore, the 4th object of the present invention is to provide the application of TetrathiazomycinA in preparing antitumor drug.
Described antitumor drug is preferably anti-glioma medicine, anti-breast cancer medicines, anti-lung-cancer medicament or medicines resistant to liver cancer.
The present invention's separation from the fermenting culture of actinomyces Marinactinospora thermotolerans SCSIO00652 obtains the new compound TetrathiazomycinA with anti-tumor activity, for new approach has been opened up in the preparation of compound TetrathiazomycinA, and compound Tetrathiazomycin A of the present invention has good anti-tumor activity, can application prepare in antitumor drug, for the exploitation of antitumor drug provides lead compound.
Actinomyces Marinactinospora thermotolerans SCSIO00652 of the present invention is known bacterial classification, is disclosed in non-patent literature: the foundation of deep-sea actinomycetes Marinactinospora thermotolerans SCSIO00652 genetic operating system. Li Jun, Zhu Qinghua, Zhang Yun, Ma Junying, Tian Xinpeng, Li Wenjun, Zhang Changsheng, bring up Jian Hua. and Chinese microbiotic magazine .2012(2) 105 ~ 111.The applicant guaranteed in 20 years, to the public, to provide this Marinactinospora thermotolerans SCSIO00652 bacterial strain from the applying date.
Accompanying drawing explanation:
Fig. 1 is the electron-microscope scanning figure of Marinactinospora thermotolerans.SCSIO00652, and wherein Figure 1A and Figure 1B are the electron-microscope scanning figure under different multiples;
Fig. 2 is the X-single crystal diffraction figure of TetrathiazomycinA.
Embodiment:
Following examples are to further illustrate of the present invention, rather than limitation of the present invention.
Embodiment 1:
Separated and the preparation of Tetrathiazomycin A
1, substratum
A, seed culture medium: in every liter of substratum, contain: starch 10g, (NH 4) 2sO 42g, K 2hPO 41g, MgSO 47H 2o1g, NaCl1g, peptone 1g, yeast extract powder 0.5g, trace element solution0.1mL, thick sea salt 30g, surplus is water, pH7.4.121 ℃, sterilizing 30min;
B, fermention medium: the same seed culture medium of filling a prescription.121 ℃, sterilizing 30min.
2, fermentation
By its electron-microscope scanning of actinomyces Marinactinospora thermotolerans.SCSIO00652(figure of activation as shown in Figure 1) in access 6L seed culture medium, 28 ° of C, 200rpm, cultivate 4d and make seed liquor, the seed liquor of 6L is linked in 60L fermention medium to 28 ° of C, 200rpm, shaking culture 7d, and make fermenting culture.
3, extraction
Fermenting culture first carries out centrifugation (4000r.min -1, 10min), fermented liquid and mycelium to be separated, fermented liquid extracts through isopyknic ethyl acetate, and ethyl acetate layer obtains extractum A (20.1g) after distillation and concentration.
4, extraction separation and evaluation compound Tetrathiazomycin A(1)
Extractum A is through purification on normal-phase silica gel column chromatography (silica gel 100 ~ 200 orders); using chloroform/methanol as eluent; from volume ratio 100:0 ~ 1:1, carry out gradient elution; collect the cut Fr.5-8 that chloroform/methanol volume ratio 92:8 ~ 1:1 gradient elution gets off, then through silica gel column chromatography, use ethyl acetate/methanol as eluent; from volume ratio 94:6 ~ 8:2, carry out gradient elution; collected volume is than the component Fr.5-8-1 of 9:1 ~ 8:2 wash-out, then through the anti-phase medium pressure liquid chromatography of ODS (S-50 μ m, 12nm; 100 * 20mm, YMC), flow velocity is 15ml/min; methanol/water gradient elution 60min with volume fraction from 10% ~ 100%, the cut that the methanol/water gradient elution of collected volume mark 80 ~ 90% gets off, finally by high performance liquid chromatography (ODS-A; 250 * 10mm, 5 μ m; YMC), flow velocity is 2.5ml/min, and the acetonitrile/water gradient elution 30min with volume fraction from 70% ~ 100%, is that 22min obtains compound 1(TetrathiazomycinA in retention time) (16mg).
By structural analysis, to the compound 1(TetrathiazomycinA preparing from the fermenting culture of Marinactinospora thermotolerans.SCSIO00652 of the present invention) to identify, its qualification result is as follows:
White solid, its nuclear magnetic data ownership is as shown in table 1, 1hNMR (500MHz, CD 3oD) and 13c NMR (125MHz, CD 3oD), in Table 1.Fusing point: 115 ~ 116 ℃.HR-ESI-MS m/z666.1382 ([M+H] +, theoretical value 666.1444). its X-single crystal diffraction figure is as shown in Figure 2.
Table 1: nuclear magnetic data compound 1(TetrathiazomycinA) ( 1h-NMR data are measured in 500MHz, are coupling constant (Hz) in bracket, 13c-NMR data are measured in 125MHz, and solvent is deuterated methanol)
Figure BDA00001851316300052
Figure BDA00001851316300061
In sum, the structural formula of authenticating compound 1 as shown in formula I, called after TetrathiazomycinA,
Figure BDA00001851316300071
The antitumor cytolytic activity of embodiment 2:Tetrathiazomycin A
Test Tetrathiazomycin A to neuroglial cytoma strain SF-268, breast cancer cell line mcf-7, inhibiting rate and the IC of the sclc cell line NCI-H460 of the National People's Congress and human liver cancer cell HepG-2 50pH-value determination pH.
Adopt international tumor cell line, that is: neuroglial cytoma strain (SF-268), breast carcinoma cell strain (MCF-7), National People's Congress's sclc cell line (NCI-H460) and human liver cancer cell (HepG-2).Test method is international srb assay: according to Growth of Cells speed, tumour cell in logarithmic phase is inoculated in to 96 orifice plates with 180 μ L/ holes, adherent growth dosing again in 24 hours (the RPMI-1640 solution of the compound 1 of different concns) 20 μ L/ holes.Each concentration is established 3 multiple holes.And establish the contrast of corresponding RPMI-1640 solvent and acellular withered hole.Tumour cell is at 37 ℃, 5% CO 2under condition, cultivate 72 hours, the nutrient solution that inclines, every hole adds the 50% cold TCA solid cell of 50 μ L, then adopts 0.4% SRB to dye 30 minutes, the acetic acid washing with 1% 5 times, dry air.The Tris solution that finally adds 200 μ L/ holes, microplate reader 570nm wavelength is measured OD value.Using cis-platinum as positive control.Experimental result is in Table 2:
Restraining effect (the IC of table 2:TetrathiazomycinA to tumor cell line 50, μ M)
Figure BDA00001851316300081
a?Positive?conrol。

Claims (5)

1. lactam compound Tetrathiazomycin A or its salt containing four thiazoles, its structural formula is as shown in (I):
Figure FDA0000407038760000011
2. the preparation method of a compound Tetrathiazomycin A claimed in claim 1, it is characterized in that, described compound Tetrathiazomycin A is that preparation separation obtains from the fermenting culture of actinomycetes Marinactinospora thermotolerans SCSIO00652, and concrete steps are as follows:
A) prepare the fermenting culture of actinomycetes Marinactinospora thermotolerans SCSIO00652, the fermented liquid of this fermenting culture and mycelium are separated, fermented liquid is extracted with ethyl acetate, and ethyl acetate obtains extractum A mutually after concentrated;
B) extractum A is through purification on normal-phase silica gel column chromatography, using chloroform/methanol as eluent, from volume ratio 100:0～1:1, carry out gradient elution, collect the cut Fr.5-8 that chloroform/methanol volume ratio 92:8～1:1 gradient elution gets off, again through silica gel column chromatography, by ethyl acetate/methanol as eluent, from volume ratio 94:6～8:2, carry out gradient elution, collected volume is than the component Fr.5-8-1 of 9:1～8:2 wash-out, again through the anti-phase medium pressure liquid chromatography of ODS, methanol/water gradient elution with volume fraction from 10%～100%, the cut that the methanol/water gradient elution of collected volume mark 80～90% gets off, finally by obtaining Tetrathiazomycin A after high-efficient liquid phase chromatogram purification.
3. preparation method as claimed in claim 2, is characterized in that, the fermenting culture of the actinomycetes Marinactinospora thermotolerans SCSIO00652 of described a) step is prepared by following method:
By in the Marinactinospora thermotolerans SCSIO00652 access seed culture medium of activation, 28 ℃, 200rpm, cultivates 4d and makes seed liquor, and seed liquor is received in fermention medium by 10% inoculum size, 28 ℃, 200rpm, shaking culture 7d, and make fermenting culture, described seed culture medium and the formula of fermention medium are all in every liter of substratum, to contain starch 10g, (NH 4) 2sO 42g, K 2hPO 41g, MgSO 47H 2o1g, NaCl1g, peptone 1g, yeast extract powder 0.5g, trace element solution0.1mL, thick sea salt 30g, surplus is water, pH7.4.
4. compound Tetrathiazomycin A claimed in claim 1 or the application of its salt in preparing antitumor drug, described antitumor drug is anti-glioma medicine, anti-breast cancer medicines, anti-lung-cancer medicament or medicines resistant to liver cancer.
The application of 5.Marinactinospora thermotolerans SCSIO00652 in preparation compound Tetrat hiazomycin A claimed in claim 1.
CN201210230665.2A 2012-07-04 2012-07-04 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs Expired - Fee Related CN102775427B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201210230665.2A CN102775427B (en) 2012-07-04 2012-07-04 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs
PCT/CN2012/087016 WO2014005408A1 (en) 2012-07-04 2012-12-20 Antibiotic tetrathiazomycin a and preparation method thereof and use in preparation of antitumour drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210230665.2A CN102775427B (en) 2012-07-04 2012-07-04 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs

Publications (2)

Publication Number Publication Date
CN102775427A CN102775427A (en) 2012-11-14
CN102775427B true CN102775427B (en) 2014-04-09

Family

ID=47120558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210230665.2A Expired - Fee Related CN102775427B (en) 2012-07-04 2012-07-04 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs

Country Status (2)

Country Link
CN (1) CN102775427B (en)
WO (1) WO2014005408A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775427B (en) * 2012-07-04 2014-04-09 中国科学院南海海洋研究所 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs
CN104257641B (en) * 2014-08-11 2016-05-11 云南西力生物技术股份有限公司 A kind of C36Polyacetylene compound and preparation thereof and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775427B (en) * 2012-07-04 2014-04-09 中国科学院南海海洋研究所 Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chung-Mao Pan等.Progress toward the synthesis of Urukthapelstatin A and two analogues.《Tetrahedron Letters》.2012,第53卷第4065-4069页.
Progress toward the synthesis of Urukthapelstatin A and two analogues;Chung-Mao Pan等;《Tetrahedron Letters》;20120529;第53卷;第4065-4069页 *
Urukthapelstatin A, a Novel Cytotoxic Substance from Marine-derived Mechercharimyces asporophorigenens YM11-542;Yoshihide Matsuo等;《J. Antibiot.》;20070430;第60卷(第4期);第251-255页 *
Yoshihide Matsuo等.Urukthapelstatin A, a Novel Cytotoxic Substance from Marine-derived Mechercharimyces asporophorigenens YM11-542.《J. Antibiot.》.2007,第60卷(第4期),第251-255页.
海洋微生物抗肿瘤天然产物研究进展;田树红等;《微生物学通报》;20070430;第34卷(第4期);第799-803页 *
田树红等.海洋微生物抗肿瘤天然产物研究进展.《微生物学通报》.2007,第34卷(第4期),第799-803页.

Also Published As

Publication number Publication date
WO2014005408A1 (en) 2014-01-09
CN102775427A (en) 2012-11-14

Similar Documents

Publication Publication Date Title
CN102516368A (en) Cyclopeptide-7 compounds and application thereof in preparation of anti-tumor medicines
CN106518643B (en) A kind of cyclopentene ketone compounds and its preparation method and application
CN102775427B (en) Antibiotic Tetrathiazomycin A and preparation method thereof and application in preparing antineoplastic drugs
CN101445499B (en) Diterpenoid antitumor compound and preparation method thereof
CN107536833B (en) Application of 4-hydroxy-2-pyridone alkaloid in preparation of anti-tumor product
CN107686816A (en) A kind of pillworm fungal component Chaetomium globosum and its application in antitumoral compounds are prepared
CN103724290B (en) Cyclopeptide compound clavatustide A as well as producing strain, preparation method and application thereof
CN105713002B (en) Antibiotic Versicoloids A and B and preparation method thereof and the application in anti-phytopathogen medicine is prepared
CN102492006B (en) Canthaxanthin compound and application of compound to preparation of antitumor drugs
CN110218200A (en) A kind of mangrove endogenetic fungus middle ring depsipeptide compound and the preparation method and application thereof
CN105399721B (en) Noval chemical compound and preparation method thereof and the application in antibacterial antineoplastic is prepared
CN107739361B (en) Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug
CN107739362B (en) Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human oesophagus cancer drug
CN102746995B (en) Preparation method for isochromophilone VIII and application of same in preparation of antineoplastic drugs
CN103145740B (en) Sulfoxide alkaloid compound as well as preparation method and application for same
CN109942658A (en) A kind of miscellaneous terpene compound and the preparation method and application thereof and anti-tumor drug
CN104370924A (en) Compounds with tumor cell proliferation resistance, and preparation method and application thereof
CN105418602A (en) Marine peptide compound, preparation method and applications thereof
CN107501072A (en) Compound colletotriconeA and preparation method thereof and the application in antineoplastic is prepared
CN103667073B (en) Huperzia serrata endogenetic epiphyte and the application in preparation pyroles liver-protecting medicine thereof
CN105837590A (en) Compound with anti-Candida albicans activity, preparation method and application thereof
CN111606796B (en) Preparation method of two kinds of oxytetracycline ketone compounds and application of oxytetracycline ketone compounds as antitumor drugs
CN103360329A (en) Phenazine compound and it application in preparation of anti-tumor drugs
CN116874417B (en) Pyridine alkaloid and application thereof in preparation of antitumor drugs
CN116041305B (en) Fermentation compound of Penicillium (Penicillium mali) and preparation method and antitumor application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20210704

CF01 Termination of patent right due to non-payment of annual fee